DS
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Signalomics for molecular tumor boards and precision oncology of breast and gynecological cancers | Molecular systems biology |  | 2025 | 37 | 14 | ||
| Personalized allele-specific antisense oligonucleotides for GNAO1-neurodevelopmental disorder | Molecular therapy. Nucleic acids | | 2025 | 15 | 6 | ||
| Cortical neurons obtained from patient-derived iPSCs with GNAO1 p.G203R variant show altered differentiation and functional properties | Heliyon | | 2024 | 240 | 56 | ||
| Zinc for GNAO1 encephalopathy : preclinical profiling and a clinical case | Med | | 2024 | 90 | 77 | ||
| Pediatric GNAO1 encephalopathies: from molecular etiology of the disease to drug discovery | Neural Regeneration Research | | 2023 | 92 | 78 | ||
| Cells of the tumor microenvironment speak the Wnt language | Trends in molecular medicine |  | 2023 | 117 | 4 | ||
| Chlorin endogenous to the north pacific brittle star ophiura sarsii for photodynamic therapy applications in breast cancer and glioblastoma models | Biomedicines | | 2022 | 483 | 128 | ||
| Mouse models characterize GNAO1 encephalopathy as a neurodevelopmental disorder leading to motor anomalies: from a severe G203R to a milder C215Y mutation | Acta neuropathologica communications | | 2022 | 258 | 123 | ||
| Marine natural products from the russian pacific as sources of drugs for neurodegenerative diseases | Marine drugs | | 2022 | 143 | 128 | ||
| Pediatric encephalopathy: cinical, biochemical and cellular insights into the role of Gln52 of GNAO1 and GNAI1 for the dominant disease | Cells | | 2021 | 381 | 149 |
